Seasonal Influenza Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis

Posted on
by

Seasonal Influenza Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis
DelveInsight’s “Seasonal Influenza Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Seasonal Influenza Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Seasonal Influenza market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Seasonal Influenza Market Forecast

 

Some of the key facts of the Seasonal Influenza Market Report: 

  • The Seasonal Influenza market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Only 49.2% of people aged 6 months and older who participated in the National Health Interview Survey (NHIS) reported having had a seasonal influenza vaccination for the flu season 2017–2018. Additionally, the NHIS indicated that their goal is to have 70% of people immunized against seasonal flu by the year 2030
  • Acute pneumonia is a diagnosis made in about 30–40% of hospitalized individuals with laboratory-confirmed influenza. These individuals who get pneumonia are more likely to be less than five years old, older than 65, Caucasian, nursing home residents, have a history of smoking and chronic lung or heart illness, and be immunocompromised
  • Key Seasonal Influenza Companies: Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis, and others
  • Key Seasonal Influenza Therapies: CD388, mRNA-1010, SAB-176, Quadrivalent influenza vaccine, TIVf, and others
  • The Seasonal Influenza epidemiology based on type-specific cases analyzed that More patients of Influenza type-A were found compared to type-B
  • The Seasonal Influenza market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Seasonal Influenza pipeline products will significantly revolutionize the Seasonal Influenza market dynamics.

 

Seasonal Influenza Overview

The World Health Organization (WHO) describes seasonal influenza as an acute respiratory infection brought on by influenza viruses that are spread throughout the globe.

 

Get a Free sample for the Seasonal Influenza Market Report 

https://www.delveinsight.com/report-store/seasonal-influenza-market

 

Seasonal Influenza Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Seasonal Influenza Epidemiology Segmentation:

The Seasonal Influenza market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Seasonal Influenza
  • Prevalent Cases of Seasonal Influenza by severity
  • Gender-specific Prevalence of Seasonal Influenza
  • Diagnosed Cases of Episodic and Chronic Seasonal Influenza

 

Download the report to understand which factors are driving Seasonal Influenza epidemiology trends @ Seasonal Influenza Epidemiology Forecast

 

Seasonal Influenza Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Seasonal Influenza market or expected to get launched during the study period. The analysis covers Seasonal Influenza market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Seasonal Influenza Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Seasonal Influenza Therapies and Key Companies

  • CD388: Cidara
  • mRNA-1010: Moderna
  • SAB-176: SAB Therapeutics
  • Quadrivalent influenza vaccine: Sinovac Biotech
  • TIV: Novartis

 

Discover more about therapies set to grab major Seasonal Influenza market share @ Seasonal Influenza Treatment Market

 

Scope of the Seasonal Influenza Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Seasonal Influenza Companies: Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis, and others
  • Key Seasonal Influenza Therapies: CD388, mRNA-1010, SAB-176, Quadrivalent influenza vaccine, TIVf, and others
  • Seasonal Influenza Therapeutic Assessment: Seasonal Influenza current marketed and Seasonal Influenza emerging therapies
  • Seasonal Influenza Market Dynamics: Seasonal Influenza market drivers and Seasonal Influenza market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Seasonal Influenza Unmet Needs, KOL’s views, Analyst’s views, Seasonal Influenza Market Access and Reimbursement 

 

To know more about Seasonal Influenza companies working in the treatment market, visit @ Seasonal Influenza Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Seasonal Influenza Market Report Introduction

2. Executive Summary for Seasonal Influenza

3. SWOT analysis of Seasonal Influenza

4. Seasonal Influenza Patient Share (%) Overview at a Glance

5. Seasonal Influenza Market Overview at a Glance

6. Seasonal Influenza Disease Background and Overview

7. Seasonal Influenza Epidemiology and Patient Population

8. Country-Specific Patient Population of Seasonal Influenza 

9. Seasonal Influenza Current Treatment and Medical Practices

10. Seasonal Influenza Unmet Needs

11. Seasonal Influenza Emerging Therapies

12. Seasonal Influenza Market Outlook

13. Country-Wise Seasonal Influenza Market Analysis (2019–2032)

14. Seasonal Influenza Market Access and Reimbursement of Therapies

15. Seasonal Influenza Market Drivers

16. Seasonal Influenza Market Barriers

17.  Seasonal Influenza Appendix

18. Seasonal Influenza Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services